Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Karl Claxton

Showing results (11-20 of 118) with videos related to

Pageof 12
Sort By:
Pharmacoeconomics|May 19, 2006
Comprehensive decision-analytic model and Bayesian value-of-information analysis: pentoxifylline in the treatment of chronic venous leg ulcersCynthia P Iglesias, Karl Claxton
BMJ (Clinical Research Ed.)|October 29, 2005
Orphan drugs and the NHS: should we value rarity?Christopher McCabe, Karl Claxton, Aki Tsuchiya
Medical Decision Making : an International Journal of the Society for Medical Decision Making|May 2, 2008
The half-life of truth: what are appropriate time horizons for research decisions?Zoe Philips, Karl Claxton, Stephen Palmer
BMJ Global Health|November 29, 2018
Estimating health opportunity costs in low-income and middle-income countries: a novel approach and evidence from cross-country dataJessica Ochalek, James Lomas, Karl Claxton
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|September 13, 2019
Estimating the Marginal Productivity of the English National Health Service From 2003 to 2012James Lomas, Stephen Martin, Karl Claxton
Lancet (London, England)|September 21, 2002
A rational framework for decision making by the National Institute For Clinical Excellence (NICE)Karl Claxton, Mark Sculpher, Michael Drummond
Medical Decision Making : an International Journal of the Society for Medical Decision Making|February 12, 2008
The value of implementation and the value of information: combined and uneven developmentElisabeth Fenwick, Karl Claxton, Mark Sculpher
International Journal of Technology Assessment in Health Care|April 11, 2008
Why licensing authorities need to consider the net value of new drugs in assigning review priorities: addressing the tension between licensing and reimbursementChristopher McCabe, Karl Claxton, Anthony O'Hagan
Zeitschrift Fur Evidenz, Fortbildung Und Qualitat Im Gesundheitswesen|December 10, 2013
When is enough evidence enough? - Using systematic decision analysis and value-of-information analysis to determine the need for further evidenceUwe Siebert, Ursula Rochau, Karl Claxton
BMJ Open|October 11, 2020
Is an ounce of prevention worth a pound of cure? A cross-sectional study of the impact of English public health grant on mortality and morbidityStephen Martin, James Lomas, Karl Claxton
Pageof 12

Showing results (11-20 of 118) with videos related to

Sort By:
Pageof 12
Pharmacoeconomics|May 19, 2006
Comprehensive decision-analytic model and Bayesian value-of-information analysis: pentoxifylline in the treatment of chronic venous leg ulcersCynthia P Iglesias, Karl Claxton
BMJ (Clinical Research Ed.)|October 29, 2005
Orphan drugs and the NHS: should we value rarity?Christopher McCabe, Karl Claxton, Aki Tsuchiya
Medical Decision Making : an International Journal of the Society for Medical Decision Making|May 2, 2008
The half-life of truth: what are appropriate time horizons for research decisions?Zoe Philips, Karl Claxton, Stephen Palmer
BMJ Global Health|November 29, 2018
Estimating health opportunity costs in low-income and middle-income countries: a novel approach and evidence from cross-country dataJessica Ochalek, James Lomas, Karl Claxton
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|September 13, 2019
Estimating the Marginal Productivity of the English National Health Service From 2003 to 2012James Lomas, Stephen Martin, Karl Claxton
Lancet (London, England)|September 21, 2002
A rational framework for decision making by the National Institute For Clinical Excellence (NICE)Karl Claxton, Mark Sculpher, Michael Drummond
Medical Decision Making : an International Journal of the Society for Medical Decision Making|February 12, 2008
The value of implementation and the value of information: combined and uneven developmentElisabeth Fenwick, Karl Claxton, Mark Sculpher
International Journal of Technology Assessment in Health Care|April 11, 2008
Why licensing authorities need to consider the net value of new drugs in assigning review priorities: addressing the tension between licensing and reimbursementChristopher McCabe, Karl Claxton, Anthony O'Hagan
Zeitschrift Fur Evidenz, Fortbildung Und Qualitat Im Gesundheitswesen|December 10, 2013
When is enough evidence enough? - Using systematic decision analysis and value-of-information analysis to determine the need for further evidenceUwe Siebert, Ursula Rochau, Karl Claxton
BMJ Open|October 11, 2020
Is an ounce of prevention worth a pound of cure? A cross-sectional study of the impact of English public health grant on mortality and morbidityStephen Martin, James Lomas, Karl Claxton
Pageof 12